HP
HealthInvest Partners Portfolio holdings
AUM
$234M
1-Year Return
10.88%
This Quarter Return
+3.3%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$47.3M
AUM Growth
+$3.96M
(+9.1%)
Cap. Flow
+$4.2M
Cap. Flow
% of AUM
8.87%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
6
Reduced
–
Closed
3
Top Buys
| 1 |
Cardinal Health
CAH
|
+$4.67M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$3.84M |
| 3 |
Gilead Sciences
GILD
|
+$2.9M |
| 4 |
Viatris
VTRS
|
+$1.45M |
| 5 |
McKesson
MCK
|
+$1.02M |
Top Sells
| 1 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$4.04M |
| 2 |
Harmony Biosciences
HRMY
|
+$3.71M |
| 3 |
Biogen
BIIB
|
+$3.26M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Utah Medical Products
UTMD
$200M
| $7.34M | 15.5% |
86,000
| – | – |
|
|
2
Bristol-Myers Squibb
BMY
$94B
| $6.97M | 14.72% |
98,000
+54,000
| +123% | +$3.84M |
|
|
3
Gilead Sciences
GILD
$142B
| $6.48M | 13.68% |
105,000
+47,000
| +81% | +$2.9M |
|
4
Cigna
CI
$80.8B
| $4.72M | 9.96% |
17,000
+3,000
| +21% | +$832K |
|
5
Zevra Therapeutics
ZVRA
$435M
| $4.68M | 9.89% |
750,000
+80,000
| +12% | +$499K |
|
|
6
Cardinal Health
CAH
$36.4B
| $4.67M | 9.86% |
+70,000
| New | +$4.67M |
|
|
7
McKesson
MCK
$88.5B
| $4.42M | 9.33% |
13,000
+3,000
| +30% | +$1.02M |
|
|
8
Viatris
VTRS
$11.6B
| $4.09M | 8.64% |
480,000
+170,000
| +55% | +$1.45M |
|
|
OPNT
9
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| $2.26M | 4.77% |
210,000
| – | – |
|
10
Aurinia Pharmaceuticals
AUPH
$1.68B
| $1.73M | 3.65% |
230,000
| – | – |
|
|
11
Biogen
BIIB
$21.2B
| – | – |
-16,000
| Closed | -$3.26M |
|
|
12
Harmony Biosciences
HRMY
$1.86B
| – | – |
-76,000
| Closed | -$3.71M |
|
|
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
| – | – |
-1,265,000
| Closed | -$4.04M |
|